Zacks Research Predicts Higher Earnings for Globus Medical

Globus Medical, Inc. (NYSE:GMED - Free Report) - Stock analysts at Zacks Research increased their Q2 2025 earnings per share (EPS) estimates for shares of Globus Medical in a research report issued on Tuesday, January 21st. Zacks Research analyst R. Department now expects that the medical device company will earn $0.86 per share for the quarter, up from their prior forecast of $0.85. The consensus estimate for Globus Medical's current full-year earnings is $2.98 per share. Zacks Research also issued estimates for Globus Medical's Q4 2025 earnings at $0.95 EPS and FY2026 earnings at $3.97 EPS.

Globus Medical (NYSE:GMED - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.18. The business had revenue of $625.71 million during the quarter, compared to the consensus estimate of $604.69 million. Globus Medical had a net margin of 3.69% and a return on equity of 9.98%. The business's quarterly revenue was up 63.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.57 earnings per share.

A number of other research analysts also recently commented on GMED. Piper Sandler upped their price objective on Globus Medical from $80.00 to $100.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. Truist Financial lifted their price objective on shares of Globus Medical from $85.00 to $90.00 and gave the company a "hold" rating in a research report on Wednesday, December 18th. Stifel Nicolaus upped their target price on shares of Globus Medical from $80.00 to $92.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th. StockNews.com cut Globus Medical from a "buy" rating to a "hold" rating in a report on Wednesday, November 20th. Finally, Canaccord Genuity Group raised their target price on Globus Medical from $92.00 to $101.00 and gave the company a "buy" rating in a research report on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, Globus Medical presently has an average rating of "Moderate Buy" and an average target price of $96.91.

Globus Medical Stock Performance

Shares of Globus Medical stock traded up $0.80 during trading hours on Wednesday, reaching $93.21. The company's stock had a trading volume of 385,699 shares, compared to its average volume of 1,357,445. Globus Medical has a one year low of $49.33 and a one year high of $93.45. The company's 50 day simple moving average is $84.43 and its 200 day simple moving average is $76.33. The stock has a market cap of $12.69 billion, a P/E ratio of 139.11, a price-to-earnings-growth ratio of 1.73 and a beta of 1.19.

Insider Activity

In other news, SVP Kelly Huller sold 5,000 shares of the business's stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $81.01, for a total transaction of $405,050.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Keith W. Pfeil sold 14,167 shares of the company's stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $88.29, for a total transaction of $1,250,804.43. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,667 shares of company stock worth $6,674,554. Insiders own 18.54% of the company's stock.

Institutional Trading of Globus Medical

Several hedge funds have recently bought and sold shares of GMED. Pacer Advisors Inc. increased its position in shares of Globus Medical by 1.5% in the fourth quarter. Pacer Advisors Inc. now owns 24,792 shares of the medical device company's stock valued at $2,051,000 after acquiring an additional 370 shares during the last quarter. KBC Group NV increased its position in shares of Globus Medical by 1.5% during the 4th quarter. KBC Group NV now owns 46,183 shares of the medical device company's stock worth $3,820,000 after purchasing an additional 678 shares during the last quarter. Encompass More Asset Management bought a new stake in shares of Globus Medical during the 4th quarter worth approximately $545,000. Fort Washington Investment Advisors Inc. OH boosted its holdings in shares of Globus Medical by 0.3% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 415,241 shares of the medical device company's stock valued at $34,345,000 after buying an additional 1,130 shares during the last quarter. Finally, Atomi Financial Group Inc. grew its stake in shares of Globus Medical by 41.9% in the fourth quarter. Atomi Financial Group Inc. now owns 5,120 shares of the medical device company's stock valued at $423,000 after buying an additional 1,512 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.